Santhosh RK

Indian science, decoded. Biotech · pharma · policy.

[Santhosh RK @Newscienceindia]

India makes ~20% of the world's generics, yet discovers a fraction of 1% of new molecules. China licenses molecules to global pharma for $130B+ a year. The future belongs to whoever owns the molecule, not the factory. #NewScienceIndia @DBTIndia @IndiaDST

[Santhosh RK @Newscienceindia]

@peptideindexhq @CDSCO_INDIA_INF Exactly right — a legal definition turns classification into documented evidence rather than marketing language. That should make it harder for one molecule to carry two regulatory identities.

[Santhosh RK @Newscienceindia]

India is finally defining biological products in law. Proposed amendments would require makers to declare drugs synthetic or biologically derived — closing the loophole that let semaglutide hold licences in both categories. @CDSCO_INDIA_INF #NewScienceIndia #Biotech

[Santhosh RK @Newscienceindia]

@DBTIndia @DBT_NBRC @TIFRScience What this means: dense-core vesicles are the tiny packets carrying our neuropeptides, the messengers behind mood, stress and hunger. AP-3 loads the right cargo into each packet. Understanding it sharpens our view of the wiring behind brain disorders.

[Santhosh RK @Newscienceindia]

First winners for India's ₹1 lakh crore RDI Fund: reportedly 7–8 biotech startups at ~₹25 crore each, term sheets signed. Now the test — does the money reach the riskiest science or the safest bets? @DBTIndia @BIRAC_2012 #NewScienceIndia #Biotech

[Santhosh RK @Newscienceindia]

Delhi hosts 3 Nobel laureates and global science leaders this October at ESTIC-2026 — research, startups, industry in one room. Convening is easy; turning lab work into products is the test. @CSIR_IND @PrinSciAdvGoI #NewScienceIndia

[Santhosh RK @Newscienceindia]

@NITIAayog What this means: the real win is not just export volume, but the shift toward higher-value products like processed foods. Value addition is what raises farmer incomes, and new FTAs open doors for exactly that.

[Santhosh RK @Newscienceindia]

Hard line on stem cell clinics: NMC says therapy allowed ONLY for approved indications — beyond that is professional misconduct. Unapproved uses stay research-only under CDSCO or DHR. Science first, hype last. @ICMRDELHI @CDSCO_INDIA_INF #NewScienceIndia #Biotech

[Santhosh RK @Newscienceindia]

ISRO just tested a rocket engine harder than it needs to — on purpose. The CE20 passed its hot test at a 220 kN uprated thrust, clearing it for LVM3-M7 in Q4 2026. The same test also proved a pressurisation module built for Gaganyaan. @isro #NewScienceIndia #SpaceTech

[ISRO @isro]

Flight acceptance hot test of CE20 cryogenic engine earmarked for the C32 upper stage of upcoming LVM3 mission at uprated thrust conditions of 220kN is successfully carried out at ISRO Propulsion Complex, Mahendragiri on September 09, 2026.

Performance of the LOX Tank Pressurization Module (LTPM) meant for the C32 stages for Gaganyaan missions was also successfully demonstrated in this test.

[Santhosh RK @Newscienceindia]

@DBTIndia @cellogenindia @BIRAC_2012 A cell engager is a matchmaker: it grabs the cancer cell with one arm and the patient's own T cells with the other, so the immune system finds and kills the tumor. As mRNA, the body makes the drug itself — faster and cheaper. Big step for lymphoma patients.

[Santhosh RK @Newscienceindia]

New customs rulebook for pharma and device imports: officers must verify a CDSCO checklist — QR codes on APIs, 60%+ shelf life, valid licences — before releasing consignments. Traceability is the gate at the border. @CDSCO_INDIA_INF #NewScienceIndia #Pharma #MedDevices

[Santhosh RK @Newscienceindia]

@isro Simple version: El Niño warms the Pacific, slows upwelling of cold nutrient-rich water, and starves the tiny phytoplankton that feed ocean life. From space, EOS-06 watches the ocean lose its green. India cares because El Niño years often bring weaker monsoons.

[Santhosh RK @Newscienceindia]

Innovation is incomplete without investment. DBT and BIRAC launched BIO-NIVESH, putting 20 biotech startups in front of 50 investors in Delhi. Bioeconomy: $10B to $195B+ in a decade. Capital is the last missing piece. @DBTIndia @BIRAC_2012 #NewScienceIndia #Biotech

[Santhosh RK @Newscienceindia]

@isro Cryogenic engines burn super-cold hydrogen and oxygen, the most efficient propellants. This hot test clears CE20 for LVM3's C32 upper stage — the part that decides how much the rocket can carry to orbit. Every heavy mission, Gaganyaan included, rides on it.

[Santhosh RK @Newscienceindia]

CDSCO is moving from 'prior approval' to 'prior intimation' for manufacturing for testing and analysis — fewer approvals, more trust in the process. Risk-based regulation speeds science without softening safety. @CDSCO_INDIA_INF #NewScienceIndia #Pharma

[Santhosh RK @Newscienceindia]

Every biotech power learned one lesson: labs don't scale, capital does. BIO-NIVESH puts 20 biotech and deep-tech startups in a room with 50 investors — aiming India's $195B bioeconomy at $300B by 2030. @DBTIndia @BIRAC_2012 #NewScienceIndia #Biotech

[DBT-BIRAC @BIRAC_2012]

Bridging Innovation & Investment through BIO-NIVESH

BIRAC is pioneering a structured platform for sustained engagement between biotech startups, investors and industry.

Moving beyond conventional pitching, BIO-NIVESH will foster two-way dialogue, investment readiness, strategic partnerships and pathways to scale and commercialisation.

#BioNivesh #BIRAC #Biotechnology #BioInnovation #Startups #Investors #Innovation #ScaleUp #BiotechStartups #Investment #DeepTech #StartupEcosystem #GovernmentOfIndia

[Santhosh RK @Newscienceindia]

India is quietly cutting red tape for medical devices: outsourced sterilisation no longer needs a separate loan licence, and EU-approved devices without a local predicate can now skip fresh clinical investigations here. @CDSCO_INDIA_INF #NewScienceIndia #MedDevices

[Santhosh RK @Newscienceindia]

@RGambhir @isro Well said. ISRO as the early customer is the real story here — it gives the terminal flight heritage, and flight heritage is what turns a good lab result into a credible global supplier.

[Santhosh RK @Newscienceindia]

India is building laser links for space. Astrogate Labs unveiled the first indigenous optical inter-satellite terminal: 10 Gbps between satellites, ISRO as customer. Lab question to flight-ready product — this is how tech nations rise. @isro #NewScienceIndia #SpaceTech

[Santhosh RK @Newscienceindia]

A US patent just landed with an Indian space startup. GalaxEye syncs optical and radar sensors so satellites see through cloud cover and darkness — weather-agnostic imaging for global markets. Deep tech, built in India. @isro #NewScienceIndia #SpaceTech

[Santhosh RK @Newscienceindia]

ISRO and DBT are taking biology to orbit: space biotech experiments, a dedicated biotech rack for the Bharatiya Antariksh Station, and biomanufacturing for long-duration missions. Space biology is now national policy. #NewScienceIndia @isro @DBTIndia